Drugs / JL14002
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07389577 | Mar 2022 → Dec 2023 | wet macular degeneration | Jecho Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JL14002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07389577 ↗ |
| Modality | Monoclonal antibody | “JL14002 monoclonal antibody injection” NCT07389577 ↗ |
| Route | Intravitreal | “Intravitreal (IVT) injection” NCT07389577 ↗ |